FAM115A inhibitors can be classified into several categories based on their targets, all affecting FAM115A either directly or indirectly. Src kinase inhibitors like Dasatinib and PD173955 target the Src family kinases, affecting the phosphorylation and, subsequently, the activation of molecules downstream, influencing FAM115A's function or stability. MEK and JNK inhibitors such as Trametinib and SP600125 alter MAPK pathways, affecting the nuclear translocation of transcription factors that may regulate FAM115A expression. PI3K and Akt inhibitors like LY294002 and GSK690693 affect Akt signaling, a pathway implicated in the phosphorylation of various proteins, including FAM115A.
JAK-STAT inhibitors like AG-490 and INCB018424 operate by blocking JAK kinases, reducing STAT3 and STAT5 activation, and thus reducing upregulation of FAM115A. WZ4003 and MLN8237 affect kinases unrelated to the aforementioned pathways but still can influence FAM115A by affecting its interaction partners or its stabilization through phosphorylation. Similarly, STO-609 and Go 6983 focus on calcium/calmodulin and PKC isoforms, respectively, and impact various cascades that could involve FAM115A. Each of these chemicals intervenes at a specific point in cellular signaling to exert their inhibitory effect on FAM115A.